{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:51:58Z","timestamp":1781502718663,"version":"3.54.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging non-Hodgkin\u2019s lymphoma that occurs exclusively in patients with breast implants. The estimated risk of developing BIA-ALCL from exposure to breast implants is largely based on approximations about patients at risk. There is a growing body of evidence regarding the presence of specific germline mutations in patients developing BIA-ALCL, rising interest regarding possible markers of genetic predisposition to this type of lymphoma. The present paper focuses attention on BIA-ALCL in women with a genetic predisposition for breast cancer. We report our experience at the European Institute of Oncology, Milan, Italy, describing a case of BIA-ALCL in a <jats:italic toggle=\"yes\">BRCA1<\/jats:italic> mutation carrier who developed BIA-ALCL 5 years after implant-based post mastectomy reconstruction. She was treated successfully with an en-bloc capsulectomy. Additionally, we review the available literature on inherited genetic factors predisposing to the development of BIA-ALCL. In patients with genetic predisposition to breast cancer (mainly <jats:italic toggle=\"yes\">TP53<\/jats:italic> and <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic> germline mutations), BIA-ALCL prevalence seems to be higher and time to onset appears to be shorter in comparison to the general population. These high-risk patients are already included in close follow-up programs allowing the diagnosis of early-stage BIA-ALCL. For this reason, we do not believe that a different approach should be followed for postoperative surveillance.<\/jats:p>","DOI":"10.1097\/cej.0000000000000809","type":"journal-article","created":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T08:00:07Z","timestamp":1688284807000},"page":"370-376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature"],"prefix":"10.1097","volume":"32","author":[{"given":"Riccardo","family":"Carbonaro","sequence":"first","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, European Institute of Oncology, IRCCS"},{"name":"University of Milan, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Accardo","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, USL Toscana centro, ospedale Santo Stefano, Prato"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mazzocconi","sequence":"additional","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, European Institute of Oncology, IRCCS"},{"name":"University of Milan, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, European Institute of Oncology, IRCCS, Milan"},{"name":"Bologna University School of Medicine, Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Onco-Hematology Division, European Institute of Oncology, IRCCS, Milan"},{"name":"Department of Health Sciences, University of Milan, Milan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Veronesi","sequence":"additional","affiliation":[{"name":"University of Milan, Milan"},{"name":"Division of Breast Surgery, European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Caldarella","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Lorenzi","sequence":"additional","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, European Institute of Oncology, IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"R1-20250527","first-page":"1","article-title":"Increasing evidence for the association of breast implant-associated anaplastic large cell lymphoma and li fraumeni syndrome.","volume":"2019","author":"Adlard","year":"2019","journal-title":"Case Rep Genet"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1128\/MCB.20.20.7450-7459.2000","article-title":"Tumor suppressor p53 is required to modulate BRCA1 expression.","volume":"20","author":"Arizti","year":"2000","journal-title":"Mol Cell Biol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.3324\/haematol.2016.146118","article-title":"Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.","volume":"101","author":"Blombery","year":"2016","journal-title":"Haematologica"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"36126","DOI":"10.18632\/oncotarget.26308","article-title":"Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.","volume":"9","author":"Blombery","year":"2018","journal-title":"Oncotarget"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2017.4510","article-title":"Breast implants and the risk of anaplastic large-cell lymphoma in the breast.","volume":"4","author":"de Boer","year":"2018","journal-title":"JAMA Oncol"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.2019004498","article-title":"Increased prevalence of BRCA1\/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast.","volume":"136","author":"de Boer","year":"2020","journal-title":"Blood"},{"key":"R8-20250527","article-title":"A case report of breast implant-associated anaplastic large-cell lymphoma in a PALB2 mutation-positive woman.","author":"Bonev","year":"2021","journal-title":"Am Surg"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"530e","DOI":"10.1097\/PRS.0000000000007240","article-title":"The crucial role of surgical treatment in BIA-ALCL prognosis in early- and advanced-stage patients.","volume":"146","author":"Campanale","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"3S","key":"R11-20250527","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1097\/PRS.0000000000005567","article-title":"Current risk estimate of breast implant-associated anaplastic large cell lymphoma in textured breast implants.","volume":"143","author":"Collett","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bjps.2019.11.064","article-title":"Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants.","volume":"73","author":"Cordeiro","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"30E","DOI":"10.1097\/PRS.0000000000007423","article-title":"Cellular and molecular mechanisms of breast implant associated anaplastic large cell lymphoma.","volume":"147","author":"DeCoster","year":"2021","journal-title":"Plast Reconstr Surg"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.14431","article-title":"Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK\/STAT signalling pathway genes, TP53 and DNMT3A.","volume":"180","author":"Di Napoli","year":"2018","journal-title":"Br J Haematol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/356215a0","article-title":"Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.","volume":"356","author":"Donehower","year":"1992","journal-title":"Nature"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/PRS.0000000000003282","article-title":"U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma.","volume":"139","author":"Doren","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-7-152","article-title":"The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.","volume":"7","author":"Friedenson","year":"2007","journal-title":"BMC Cancer"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4274\/ejbh.galenos.2021.2021-5-6","article-title":"New data on the epidemiology of breast implant-associated anaplastic large cell lymphoma.","volume":"17","author":"Ionescu","year":"2021","journal-title":"Eur J Breast Health"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2008.585","article-title":"Anaplastic large-cell lymphoma in women with breast implants.","volume":"300","author":"de Jong","year":"2008","journal-title":"JAMA"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"104982","DOI":"10.1016\/j.yrtph.2021.104982","article-title":"Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: Report of the scientific committee on health, emerging and environmental risks (SCHEER).","volume":"125","author":"de Jong","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00006534-199708000-00065","article-title":"Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant.","volume":"100","author":"Keech","year":"1997","journal-title":"Plast Reconstr Surg"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/GOX.0000000000000268","article-title":"Breast implant-associated anaplastic large cell lymphoma: updated results from a structured expert consultation process.","volume":"3","author":"Kim","year":"2015","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R27-20250527","first-page":"360","article-title":"Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.","volume":"135","author":"Laurent","year":"2020","journal-title":"Blood"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/his.12737","article-title":"Breast-implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome.","volume":"67","author":"Lee","year":"2015","journal-title":"Histopathology"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/asj\/sjz333","article-title":"Breast implant-associated anaplastic large cell lymphoma in australia: a longitudinal study of implant and other related risk factors.","volume":"40","author":"Loch-Wilkinson","year":"2020","journal-title":"Aesthet Surg J"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.breast.2022.11.009","article-title":"Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL.","volume":"66","author":"Longo","year":"2022","journal-title":"Breast"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/PRS.0000000000005500","article-title":"The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants.","volume":"143","author":"Magnusson","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bjps.2020.02.040","article-title":"Editorial on the article \u201cRisk of breast implant associated anaplastic large cell lymphoma in a cohort of 3546 women prospectively followed long term after reconstruction with macro-textured breast implants.","volume":"73","author":"Mercer","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.","volume":"32","author":"Miranda","year":"2014","journal-title":"J Clin Oncol"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","article-title":"Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.","volume":"132","author":"Oishi","year":"2018","journal-title":"Blood"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13000-018-0688-x","article-title":"Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report.","volume":"13","author":"Pastorello","year":"2018","journal-title":"Diagn Pathol"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1177\/0003134820951422","article-title":"Breast implant associated anaplastic large cell lymphoma (BIA-ALCL).","volume":"88","author":"Perry","year":"2022","journal-title":"Am Surg"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/asj\/sjac133","article-title":"2022 practice recommendation updates from the world consensus conference on BIA-ALCL.","volume":"42","author":"Santanelli di Pompeo","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/asj\/sjaa285","article-title":"Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): review of epidemiology and prevalence assessment in Europe.","volume":"41","author":"Santanelli di Pompeo","year":"2021","journal-title":"Aesthet Surg J"},{"key":"R41-20250527","first-page":"sjac312","article-title":"BIA-ALCL epidemiological findings from a retrospective study of 248 cases extracted from relevant case reports and series: a systematic review.","author":"Santanelli di Pompeo","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/PRS.0000000000003233","article-title":"Global adverse event reports of breast implant-associated ALCL: an international review of 40 Government Authority Databases.","volume":"139","author":"Srinivasa","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/asj\/sjz021","article-title":"Differences in human leukocyte antigen expression between breast implant-associated anaplastic large cell lymphoma patients and the general population.","volume":"39","author":"Tevis","year":"2019","journal-title":"Aesthet Surg J"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"785887","DOI":"10.3389\/fonc.2021.785887","article-title":"Current progress in breast implant-associated anaplastic large cell lymphoma.","volume":"11","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2020.00301","article-title":"Molecular mechanisms of PALB2 function and its role in breast cancer management.","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:06:32Z","timestamp":1748361992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000809","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}